Astrazeneca Plc · LSE:AZN
Astrazeneca — Investor Presentation (August 2016)
21 slides from Astrazeneca's investor presentation, Aug 7, 2016
Slide 1: A focused biopharmaceutical company
A focused biopharmaceutical company General presentation 07 August 2016
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: This document contains certain forward-looking statements with respect to the operations,
Slide 3: Strategic priorities
Strategic priorities Achieve 1 Return 2 3 Be a great scientific to growth place to work leadership 3
Slide 4: New Cambridge, UK R&D centre and HQ
New Cambridge, UK R&D centre and HQ Scientific collaborations key driver behind move 4
Slide 5: Focused strategy: Three therapy areas
Focused strategy Three therapy areas Respiratory, Cardiovascular & Inflammation & Oncology Metabolic Disease Autoimmunity Commitment to further focus the portfolio 5
Slide 6: Pipeline value unlocked
R&D productivity increase Publications Phase III / Registration NMEs Unlocking pipeline value 552 15 13 Pipeline value 11 unlocked 397 Pipeline value unlocked 7 7 6 2010 2015 2015 2010 2010 2011 2012 2013 2014 2015 High-impact publications Registration Phase III 2015 2016 2017 2018 Medium-impact p
Slide 7: Delivering the late-stage pipeline
Delivering the late-stage pipeline saxa/dapa brodalumab Tagrisso durvalumab benralizumab saxa/dapa submission EU submission US, EU approval US,EU,JP Breakthrough US Phase III positive positive opinion EU (type-2 diabetes) (psoriasis) (lung cancer) (bladder cancer) (severe asthma) (type-2 diabetes
Slide 8: Key late-stage medicines & lifecycle
Key late-stage medicines & lifecycle Phase III trials or under regulatory review* Respiratory & Cardiovascular & Oncology Infection, Autoimmunity Metabolic Diseases Neuroscience (opportunistic) brodalumab* ZS-9* cediranib* AZD3293 (psoriasis) (hyperkalaemia) (ovarian cancer) (Alzheimer’s disease)
Slide 9: Full pipeline of new medicines (NMEs)
Full pipeline of new medicines (NMEs) RIA CVMD Oncology Infection, Neuroscience, Gastrointestinal 1 Includes significant fixed-dose combination projects, and parallel indications that are in a separate therapy area (See LCM chart for other parallel indications and oncology combination projects) # P
Slide 10: Pipeline newsflow in 2016 & 2017
Pipeline newsflow in 2016 & 2017 Realising potential of new medicines H2 2016 H1 2017 H2 2017 Regulatory decisions cediranib - ovarian cancer (EU) brodalumab - psoriasis (EU) - brodalumab - psoriasis (US) saxa/dapa - type-2 diabetes (US) ZS-9 - hyperkalaemia (EU) Regulatory submissions benra
Slide 11: Growth platforms
Growth platforms New Oncology added in 2016 FY 2015 % % Total Q4 2015 % $m change Revenue $m change Growth Platforms 14,003 +11 57 3,588 +11 Respiratory 4,987 +7 - 1,289 +4 Brilinta/Brilique 619 +44 - 174 +43 Diabetes 2,224 +26 - 585 +24 Emerging Markets 5,822 +12 - 1,428 +10 Japan 2,020 +4 - 5
Slide 12: Building a pure-play innovator in three therapy areas
Building a pure-play innovator in three therapy areas Focusing and slimming down portfolio to optimise resource allocation ü BACE inhibitor 1. Accessing ü Brodalumab Therapy Area (TA) ü Tralokinumab (AD1) capability / upside ü Durvalumab (haematology) Recurring • R&D investment revenue in main
Slide 13: Emerging Markets: Geographic platform for growth
Emerging Markets Geographic platform for growth China 11% of Europe Product Sales US 23% of Product Sales Japan 40% of 9% of Product Product Sales Sales Emerging Rest of Markets World (ex-China) Established 14% of (ex-Japan) Product Sales 4% of 2015 Product Sales as reported Product Sales 13
Slide 14: Emerging Markets: Primary care key to success
Emerging Markets Primary care key to success 6% 47% Asia $100-130bn 53% growth 94% North America 24% Europe $115-145bn $25-35bn growth 76% growth 7% 8% AFME 93% $15-25bn Specialty Care Latin growth America Primary Care $25-35bn growth 92% 40% World 60% $305-335bn growth Share of absolute growt
Slide 15: Profit & Loss: Leveraging top-line resilience
Profit & Loss Leveraging top-line resilience FY 2015 % % Total Q4 2015 % $m change Revenue $m change Total Revenue 24,708 +1 100 6,399 +2 Product Sales 23,641 (1) 96 6,207 - Externalisation Revenue 1,067 +140 4 192 +490 Core Cost of Sales (4,119) (6) 17 (1,209) +3 Core Gross Profit 20,589 +2 831 5
Slide 16: Great place to work
Great place to work Gothenburg, Sweden Cambridge, UK Gaithersburg, US Strategic R&D Centre Headquarters Strategic R&D Centre 16
Slide 17: Great place to work: Realising company vision
Great place to work Realising company vision 1. A passion for people 2. Strong, supportive, development leadership at all levels 6. Access to medicines Values and 3. Flawless technology & social responsibility Purpose and ways of working 5. Environmental 4. Energizing sites and sustainability workpl
Slide 18: Great place to work
Great place to work Employee engagement in line with Awards for overall work environment best-performing companies 85% 86% Employee Belief in the strategy engagement (18% increase) (8% increase) 88% Scientific and patient orientation (12% increase) 18
Slide 19: On track to deliver long-term goals
On track to deliver long-term goals >$45bn in 2023 2012-2014 2015-2017 2018+ Building strong Delivering on return Sustainable delivery foundations to growth and growth Target is at constant exchange rates (2013) which is equivalent to ~$40bn at current exchange rates 19
Slide 20: Investor Relations
Investor Relations About AstraZeneca Investor Relations AstraZeneca is a global, science-led biopharmaceutical Cambridge, UK company that focuses on the discovery, development and Thomas Kudsk Larsen +44 203 749 5712 commercialisation of prescription medicines, primarily for the Craig Marks +44 788
Slide 21: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or dis